|
|
|
|
Ther Drug Monit 2009,Dec,01;31(6):695-702; (PMID: 19865000)
[...] (LC-MS/MS) method was developed for the quantification of raltegravir, etravirine, and 9 other antiretroviral agents (amprenavir, atazanavir, darunavir, efavirenz, indinavir, lopinavir, ritonavir, saquinavir, and [...]
|
|
|
Antimicrob Agents Chemother 2009,Dec,01;53(12):5185-96; (PMID: 19667283)
[...] 700 mg twice daily plus ritonavir 100 mg once daily delivered 17% higher values for the maximum plasma amprenavir concentration at the steady state (C(max)), 22% higher values for the area under the plasma concentration versus time curve over the dosing interval at the steady state [AUC(0-tau)], similar values for the concentration at the end of the dosing interval (C(tau)), and 114% higher unbound C(tau) values.[...]
|
|
|
J Chromatogr B Analyt Technol Biomed Life Sci 2009,Oct,01;877(27):3072-82; (PMID: 19699694)
[...] assay for simultaneous determination of the plasma concentration of 11 antiretroviral agents (nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc) has been developed.[...]
|
|
|
Atherosclerosis 2009,Oct,01;206(2):439-43; (PMID: 19356757)
[...]METHODS: The effect of pharmacological concentrations of seven commonly used antiretroviral compounds, Stavudine, Efavirenz, Nevirapine, Lopinavir, Amprenavir, Nelfinavir and Ritonavir, on cholesterol efflux from RAW 264.7 mouse macrophages and human[...]
|
|
|
J Acquir Immune Defic Syndr 2009,Sep,01;52(1):56-63; (PMID: 19731418)
[...]) and the CNS penetration-effectiveness (CPE) score: a summary score of 1 (high: zidovudine, abacavir, nevirapine, amprenavir-ritonavir, atazanavir-ritonavir, indinavir-ritonavir, and lopinavir-ritonavir), 0.5 (intermediate: stavudine, lamivudine, emtricitabine, [...]
|
|
|
Rev Med Virol 2009,Sep,01;19(5):287-99; (PMID: 19714702)
[...]etravirine; ten protease inhibitors (PIs): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir; one fusion inhibitor (FI): [...]
|
|
|
J Antimicrob Chemother 2009,Aug,01;64(2):398-410; (PMID: 19515730)
[...]A lower baseline background drug resistance and higher fosamprenavir genotypic inhibitory quotient led to better antiviral responses. The plasma amprenavir trough concentartion (C(tau)) was 49% higher in the HD-FPV/RTV arm than in the STD-[...]
|
|
|
Pharmacotherapy 2009,Aug,01;29(8):937-42; (PMID: 19637947)
STUDY OBJECTIVE: To quantify the pharmacokinetics of amprenavir and atazanavir (administered as the prodrug fosamprenavir) alone and in combination in human immunodeficiency virus[...]
|
|
|
Fundam Clin Pharmacol 2009,Aug,01;23(4):423-5; (PMID: 19709321)
[...]At the time of surgery, the patient was on quadruple antiretroviral therapy (lamivudine, zidovudine, and amprenavir/ritonavir). Immunosuppression was initiated with basiliximab, corticosteroid, mycophenolate mofetil, and a single 0.5 mg dose of [...]
|
|
|
J Chem Inf Model 2009,Jul,01;49(7):1751-61; (PMID: 19537723)
[...] protease complexes were used to estimate the influence of different drug resistance-associated mutations in lopinavir, amprenavir, saquinavir, and atazanavir protease recognition. In agreement with virological and clinical data, the structural analysis showed that the single mutations V82A, I84V, and M46I are associated with higher energetic values for all analyzed complexes with respect to wild-type, indicating their decreased stability.[...]
|
 1 2 3 4 5 6 7 8 
|
|
